The POSEIDON trial also suggested that in patients with advanced NSCLC, chemotherapy combined with PD‐L1 and CTLA‐4 inhibitors (triple combination: carboplatin + paclitaxel + durvalumab + tremelimumab) offers durable long‐term OS benefits compared with chemotherapy alone.238. The gene discussed is CTLA4; the disease is non-small cell lung carcinoma.